CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 86 enrolled
Drug / intervention
Transcranial Direct Current Stimulation (tDCS)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02168400
NCT02168400N/ACompleted

Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Alcohol Use Disorder

University of Minnesota·interventional·Posted Jun 20, 2014·Updated Jun 5, 2024

In Brief

A clinical study evaluating Transcranial Direct Current Stimulation (tDCS) for Alcohol Use Disorder and 2 related conditions. Completed, enrolled 86 participants across 1 site.

Detailed Summary

Long-term abstinence from alcohol is supported by a compensatory mechanism in functional brain connectivity, a potential brain biomarker that could be an intervention target. These findings provide a compelling case to explore whether this brain biomarker can be modulated to enhance patients' ability to remain abstinent. There is a need to investigate methods that can be used to increase functional brain connectivity. The overall objective of this proposal is to enhance brain functional connectivity in short-term abstinent alcoholics as a therapeutic intervention that supports abstinence.

Study Details

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 20, 2014
Enrollment StartJul 7, 2016
Primary CompletionNov 17, 2022
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 12.0 years ago

Interventions

Transcranial Direct Current Stimulation (tDCS)device

tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.